Summit Therapeutics (SMMT) Accumulated Depreciation & Amortization (2019 - 2024)
Historic Accumulated Depreciation & Amortization for Summit Therapeutics (SMMT) over the last 6 years, with Q4 2024 value amounting to $1.1 million.
- Summit Therapeutics' Accumulated Depreciation & Amortization rose 729.37% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.1 million, marking a year-over-year increase of 729.37%. This contributed to the annual value of $1.1 million for FY2024, which is 729.37% up from last year.
- Summit Therapeutics' Accumulated Depreciation & Amortization amounted to $1.1 million in Q4 2024, which was up 729.37% from $1.0 million recorded in Q4 2023.
- In the past 5 years, Summit Therapeutics' Accumulated Depreciation & Amortization registered a high of $1.3 million during Q4 2022, and its lowest value of $1.0 million during Q4 2021.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $1.1 million (2024), whereas its average is $1.1 million.
- As far as peak fluctuations go, Summit Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 261661.56% in 2020, and later plummeted by 1966.08% in 2023.
- Over the past 5 years, Summit Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $1.1 million in 2020, then fell by 8.24% to $1.0 million in 2021, then increased by 25.19% to $1.3 million in 2022, then fell by 19.66% to $1.0 million in 2023, then increased by 7.29% to $1.1 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $1.1 million for Q4 2024, versus $1.0 million for Q4 2023 and $1.3 million for Q4 2022.